Arbutus Biopharma Corporation ABUS Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's accretion (amortization) of discounts and premiums, investments?
- Arbutus Biopharma Corporation (ABUS) reported accretion (amortization) of discounts and premiums, investments of $354K in Q1 2026.
- How has Arbutus Biopharma Corporation's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Arbutus Biopharma Corporation's accretion (amortization) of discounts and premiums, investments decreased by 50.7% year-over-year, from $718K to $354K.
- What is the long-term trend for Arbutus Biopharma Corporation's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's accretion (amortization) of discounts and premiums, investments has grown at a 23.8% compound annual growth rate (CAGR), from -$999K to $2.35M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to the carrying value of investment securities as they approach maturity, reflecting the amortization of premiums or accretion of discounts. It bridges the gap between the interest income reported on the income statement and the actual cash yield received from the investment portfolio. This metric is vital for understanding the effective return on the company's cash reserves.